应用IA方案和DA方案诱导缓解急性髓系白血病疗效观察

摘要

目的：比较应用去甲氧柔红霉素联合阿糖胞苷（I A）方案和柔红霉素联合阿糖胞苷（D A）方案诱导缓解急性髓系白血病（Acute myeloid leukemia，AML）的临床疗效。方法：选取我院2011年5月至2012年5月收治的84例AML患者，随机分为IA组与DA组，各42例，分别以IA方案与D A方案进行化疗。比较两组患者临床疗效、不良反应及生存情况。结果：I A组总有效率为95.2%，显著高于D A组的61.9%，差异有显著统计学意义（P＜0.01）。两组患者不良反应发生率与持续时间比较，差异均无统计学意义（P＞0.05）。IA组3年生存率为81.0%，显著高于DA组的38.1%，差异有统计学意义（P＜0.05）。结论：I A方案较D A方案能够更为明显地缓解A M L患者临床症状，改善其生存情况，其安全性与DA方案相仿，不良反应可耐受，可作为AML诱导缓解首选方案。%Objective:To compare the clinical efficacy of IA and DA in the treatment of acute myeloid leukemia (AML). Methods:84 AML patients were randomly divided into IA group and DA group, 42 cases were treated with IA and 42 cases were treated with DA. The clinical efifcacy, adverse reactions and survival of the two groups were compared. Results:The total effective rate of IA group was 95.2%, signiifcantly higher than 61.9%in DA group (P<0.01).The incidence of adverse reactions in the two groups was not statistically signiifcant (P>0.05). The 3 year survival rate of IA group was 81%, which was signiifcantly higher than that was 38.1%of DA group (P<0.05). Conclusion:Compared with DA scheme , the IA scheme can relieve the clinical symptoms of AML patients more obviously, and improve the survival of patients. The security of IA scheme is similar to that of DA scheme, and the adverse reactions can be tolerated, IA scheme can be used as the ifrst choice for AML patients.